Photo of Shubh Goel taken from LinkedIn
Feb 27, 2024, 05:27
Shubh Goel: Recently, I spoke to a Pharmaceutical Executive following data presented at ASCO GI from our EMERALD-1 and MATTERHORN Phase III trials
Shubh Goel, VP and US Franchise Head, Immuno-Oncology and GI Tumors at
“This post is intended for a US audience. Recently, I spoke to a Pharmaceutical Executive following data presented at ASCO GI from our EMERALD-1 and MATTERHORN Phase III trials, in liver cancer and gastric cancer, respectively.
At AstraZeneca, we believe if we can intervene earlier, we have a better chance of improving long-term outcomes for patients, so it was great to share more about our extensive clinical development program to treat GI cancers earlier. Thanks for chatting with me, Donald Tracy!”
Source: Shubh Goel/LinkedIn